Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Reporting from ASH 2017 on Chronic Lymphocytic Leukaemia, Christian Buske discusses studies investigating chemo-free approaches aiming to achieve MRD negativity and/or stopping treatment. Increased MRD negativity was shown in MURANO with venetoclax+rituximab vs bendamustine+rituximab and in CLARITY with ibrutinib+venetoclax.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
